Potential Clinical Targets of Repetitive Transcranial Magnetic Stimulation Treatment in Schizophrenia

• Published in: Neuropsychobiology Vol. 54; no. 2; pp. 87 - 99
• Main Authors: Cordes, J., Arends, M., Mobascher, A., Brinkmeyer, J., Kornischka, J., Eichhammer, P., Klimke, A., Winterer, G., Agelink, M.W.
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland Karger 01.01.2006; S. Karger AG
• Subjects: Adult and adolescent clinical studies; Behavioral psychophysiology; Biological and medical sciences; Fundamental and applied biological sciences. Psychology; Humans; Medical sciences; MEDLINE; Meta-Analysis as Topic; Psychology. Psychoanalysis. Psychiatry; Psychology. Psychophysiology; Psychopathology. Psychiatry; Psychoses; Review; Schizophrenia; Schizophrenia - therapy; Transcranial Magnetic Stimulation - methods; Schizophrenia; Repetitive transcranial magnetic stimulation; Psychosis; Treatment; Transcranial magnetic stimulation; Magnetic stimulus
• ISSN: 0302-282X; 1423-0224
• DOI: 10.1159/000096990

Despite the introduction of atypical antipsychotic drugs, treatment-resistant symptoms still represent a serious problem in schizophrenia. Currently, there is evidence from clinical studies suggesting that treatment with repetitive transcranial magnetic stimulation (rTMS) may improve schizophrenia symptoms. Our review provides an overview of clinical rTMS studies in schizophrenic patients. A systematic search of the literature (Cochrane and Medline databases up to December 2005) was conducted. Most studies showed methodological problems due to their explorative character and small sample sizes. In some studies, a treatment effect of high-frequency rTMS applied over the prefrontal cortex was seen with respect to negative symptoms. On the other hand, low-frequency rTMS in the temporal lobe area might lead to a suppression of auditory hallucinations. It is concluded that larger sham-controlled studies are required to allow an adequate assessment of the clinical and neurobiological effects of rTMS in schizophrenic patients. The currently available data provide insufficient evidence to support the use of rTMS as an adjuvant treatment for schizophrenic psychopathology, but encourage further investigation of rTMS as a novel treatment approach.